JPWO2020127503A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020127503A5 JPWO2020127503A5 JP2021534948A JP2021534948A JPWO2020127503A5 JP WO2020127503 A5 JPWO2020127503 A5 JP WO2020127503A5 JP 2021534948 A JP2021534948 A JP 2021534948A JP 2021534948 A JP2021534948 A JP 2021534948A JP WO2020127503 A5 JPWO2020127503 A5 JP WO2020127503A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- combination
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 62
- 102000004965 antibodies Human genes 0.000 claims description 55
- 108090001123 antibodies Proteins 0.000 claims description 55
- 239000000427 antigen Substances 0.000 claims description 43
- 102000038129 antigens Human genes 0.000 claims description 43
- 108091007172 antigens Proteins 0.000 claims description 43
- 239000003112 inhibitor Substances 0.000 claims description 39
- 230000002401 inhibitory effect Effects 0.000 claims description 39
- 102100005830 CD70 Human genes 0.000 claims description 30
- 101700017377 CD70 Proteins 0.000 claims description 30
- 230000036210 malignancy Effects 0.000 claims description 30
- 102100013894 BCL2 Human genes 0.000 claims description 28
- 108060000885 BCL2 Proteins 0.000 claims description 28
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 25
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 25
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 13
- 229960003603 decitabine Drugs 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 229960002756 Azacitidine Drugs 0.000 claims description 11
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 11
- LQBVNQSMGBZMKD-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical group C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 229960001183 venetoclax Drugs 0.000 claims description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 102100009178 RUNX1T1 Human genes 0.000 claims description 6
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical class O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 4
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 4
- 208000000214 Leukemia, Myelomonocytic, Chronic Diseases 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 4
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims description 4
- 201000007224 myeloproliferative neoplasm Diseases 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- WIJZXSAJMHAVGX-DHLKQENFSA-N (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide Chemical compound FC1=CN=CC(N([C@H](C(=O)NC2CC(F)(F)C2)C=2C(=CC=CC=2)Cl)C(=O)[C@H]2N(C(=O)CC2)C=2N=CC=C(C=2)C#N)=C1 WIJZXSAJMHAVGX-DHLKQENFSA-N 0.000 claims description 2
- SFNSLLSYNZWZQG-VQIMIIECSA-N 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea Chemical compound N([C@@H]1CCN([C@H](C1)C=1NC2=CC=CC=C2N=1)C)C(=O)NC1=CC=C(C#N)C=C1 SFNSLLSYNZWZQG-VQIMIIECSA-N 0.000 claims description 2
- GYQYAJJFPNQOOW-UHFFFAOYSA-N 6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 claims description 2
- 102000004400 Aminopeptidases Human genes 0.000 claims description 2
- 108090000915 Aminopeptidases Proteins 0.000 claims description 2
- 102000001805 Bromodomains Human genes 0.000 claims description 2
- 108050009021 Bromodomains Proteins 0.000 claims description 2
- 102100016493 CD33 Human genes 0.000 claims description 2
- 101700017647 CD33 Proteins 0.000 claims description 2
- 229960000684 Cytarabine Drugs 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- 229960000975 Daunorubicin Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 Etoposide Drugs 0.000 claims description 2
- 230000035693 Fab Effects 0.000 claims description 2
- 229950006304 Gilteritinib Drugs 0.000 claims description 2
- 229950003566 Glasdegib Drugs 0.000 claims description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 2
- 229960000908 Idarubicin Drugs 0.000 claims description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 2
- 229950010738 Ivosidenib Drugs 0.000 claims description 2
- 229950010895 Midostaurin Drugs 0.000 claims description 2
- 229960001156 Mitoxantrone Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 102000003800 Selectins Human genes 0.000 claims description 2
- 108090000184 Selectins Proteins 0.000 claims description 2
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 claims description 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 2
- 230000021615 conjugation Effects 0.000 claims description 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229960000390 fludarabine Drugs 0.000 claims description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims description 2
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 229950010133 Enasidenib Drugs 0.000 claims 1
- 102100007467 NEDD8 Human genes 0.000 claims 1
- 108010072790 NEDD8 Protein Proteins 0.000 claims 1
- 229950010588 Pevonedistat Drugs 0.000 claims 1
- MPUQHZXIXSTTDU-QXGSTGNESA-N [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound C1[C@H](O)[C@H](COS(=O)(=O)N)C[C@H]1N1C2=NC=NC(N[C@@H]3C4=CC=CC=C4CC3)=C2C=C1 MPUQHZXIXSTTDU-QXGSTGNESA-N 0.000 claims 1
- 230000003213 activating Effects 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 229910021320 cobalt-lanthanum-strontium oxide Inorganic materials 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 150000001875 compounds Chemical group 0.000 description 4
- 230000002829 reduced Effects 0.000 description 4
- 210000002397 Granulocyte Precursor Cells Anatomy 0.000 description 3
- 210000001167 myeloblast Anatomy 0.000 description 3
- 230000002195 synergetic Effects 0.000 description 3
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 210000000440 Neutrophils Anatomy 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940085936 cusatuzumab Drugs 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1820582.3A GB201820582D0 (en) | 2018-12-18 | 2018-12-18 | CD70 combination therapy |
| GB1820582.3 | 2018-12-18 | ||
| GB1911007.1 | 2019-08-01 | ||
| GBGB1911007.1A GB201911007D0 (en) | 2019-08-01 | 2019-08-01 | CD70 combination therapy |
| GBGB1917701.3A GB201917701D0 (en) | 2019-12-04 | 2019-12-04 | CD70 Combination therapy |
| GB1917701.3 | 2019-12-04 | ||
| PCT/EP2019/085982 WO2020127503A1 (en) | 2018-12-18 | 2019-12-18 | Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022515077A JP2022515077A (ja) | 2022-02-17 |
| JPWO2020127503A5 true JPWO2020127503A5 (da) | 2022-12-27 |
Family
ID=69104399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534948A Pending JP2022515077A (ja) | 2018-12-18 | 2019-12-18 | 急性骨髄性白血病の治療のための、ｃｄ７０及びベネトクラクス、ｂｃｌ－２阻害剤、組合せ療法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11712468B2 (da) |
| EP (2) | EP4218761A1 (da) |
| JP (1) | JP2022515077A (da) |
| KR (1) | KR20210106428A (da) |
| CN (2) | CN113226317B (da) |
| AU (1) | AU2019409936A1 (da) |
| BR (1) | BR112021011684A2 (da) |
| CA (1) | CA3117282A1 (da) |
| DK (1) | DK3890740T3 (da) |
| ES (1) | ES2941638T3 (da) |
| FI (1) | FI3890740T3 (da) |
| HU (1) | HUE061710T2 (da) |
| IL (1) | IL284015A (da) |
| LT (1) | LT3890740T (da) |
| MX (1) | MX2021007350A (da) |
| PL (1) | PL3890740T3 (da) |
| PT (1) | PT3890740T (da) |
| SG (1) | SG11202105197UA (da) |
| TW (1) | TW202038958A (da) |
| UY (1) | UY38511A (da) |
| WO (1) | WO2020127503A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202038958A (zh) | 2018-12-18 | 2020-11-01 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
| US20220249528A1 (en) * | 2019-06-20 | 2022-08-11 | Celgene Corporation | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
| TW202138388A (zh) * | 2019-12-30 | 2021-10-16 | 美商西根公司 | 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法 |
| EP4204098A1 (en) * | 2020-08-29 | 2023-07-05 | Argenx BV | Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor |
| CA3222020A1 (en) * | 2021-07-21 | 2023-01-26 | Emory University | Bak activators, pharmaceutical compositions, and uses in treating cancer |
| WO2023031403A1 (en) * | 2021-09-02 | 2023-03-09 | F. Hoffmann-La Roche Ag | Antibodies for the treatment of aml |
| WO2023081721A1 (en) * | 2021-11-03 | 2023-05-11 | Board Of Regents, The University Of Texas System | Methods relating to treatment of acute myeloid leukemia |
| TW202340177A (zh) | 2021-12-30 | 2023-10-16 | 美商拜歐米富士恩股份有限公司 | 作為 flt3抑制劑之吡嗪化合物 |
| CN114949230A (zh) * | 2022-06-13 | 2022-08-30 | 厦门大学附属第一医院 | 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用 |
| CN117771177A (zh) * | 2023-08-02 | 2024-03-29 | 首都医科大学附属北京儿童医院 | 维奈克拉自微乳化释药系统及其制备方法和应用 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5573924A (en) | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
| DE19747418C1 (de) | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
| US6500633B1 (en) | 2000-04-26 | 2002-12-31 | Atairgin Technologies, Inc. | Method of detecting carcinomas |
| US20030148321A1 (en) | 2001-08-24 | 2003-08-07 | Iris Pecker | Methods and kits for diagnosing and monitoring hematopoietic cancers |
| AU2002351828A1 (en) | 2001-11-05 | 2003-05-19 | Deutsches Krebsforschungszentrum | Novel genetic markers for leukemias |
| US7261892B2 (en) | 2001-11-27 | 2007-08-28 | Celltech R&D Limited | Methods for diagnosis and treatment of epithelial-derived cancers |
| JP4446036B2 (ja) | 2001-11-27 | 2010-04-07 | ウーセーベー ファルマ ソシエテ アノニム | 上皮誘導性癌の治療のための薬剤組成物 |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US8039218B2 (en) | 2002-11-14 | 2011-10-18 | John Wayne Cancer Institute | Detection of cancer cells in body fluids |
| WO2004073656A2 (en) | 2003-02-20 | 2004-09-02 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| US20080025989A1 (en) | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| EA010350B1 (ru) | 2004-06-03 | 2008-08-29 | Новиммун С.А. | Антитела против cd3 и способы их применения |
| CA2583208C (en) | 2004-10-15 | 2015-08-25 | Seattle Genetics, Inc. | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| US8337838B2 (en) | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| US7641903B2 (en) | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| EP1872124A4 (en) | 2005-04-19 | 2008-06-11 | Prediction Sciences Llc | DIAGNOSTIC MARKERS FOR THE TREATMENT AND EVOLUTION OF BREAST CANCER AND METHODS OF USE |
| DK1871418T3 (da) | 2005-04-19 | 2014-06-10 | Seattle Genetics Inc | Humaniserede anti-cd70-bindende midler og anvendelser deraf |
| WO2007011856A2 (en) | 2005-07-15 | 2007-01-25 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for differential diagnosis of chronic lymphocytic leukemia |
| AU2006294663B2 (en) | 2005-09-26 | 2012-03-22 | Medarex, Inc. | Human monoclonal antibodies to CD70 |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| KR101571027B1 (ko) | 2006-06-12 | 2015-11-23 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | 효과기 기능을 갖는 단일쇄 다가 결합 단백질 |
| CN101489697B (zh) | 2006-07-24 | 2011-06-01 | 千田建设股份有限公司 | 金属线材除锈的方法及其装置 |
| ES2523915T5 (es) | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
| EP2097534A4 (en) | 2006-12-14 | 2010-05-12 | Medarex Inc | HUMAN ANTIBODIES BINDING TO CD70 AND USES THEREOF |
| KR100807069B1 (ko) | 2007-09-21 | 2008-02-25 | 고려대학교 산학협력단 | 암 치료용 의약 조성물 |
| US20100267626A1 (en) | 2007-11-05 | 2010-10-21 | Novartis Ag | Methods and compositions for measuring wnt activation and for treating wnt-related cancers |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| WO2010014948A1 (en) | 2008-08-01 | 2010-02-04 | The University Of Utah Research Foundation | Methods of treatment using wnt inhibitors |
| WO2010019921A2 (en) | 2008-08-15 | 2010-02-18 | The Regents Of The University Of California | Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia |
| WO2010037041A2 (en) | 2008-09-26 | 2010-04-01 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| ES2571235T3 (es) | 2009-04-10 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3 |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP2987487B1 (en) | 2009-08-10 | 2020-10-07 | Samumed, LLC | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| WO2011035433A1 (en) | 2009-09-23 | 2011-03-31 | University Health Network | Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers |
| KR101773216B1 (ko) | 2009-12-29 | 2017-08-31 | 교와 핫꼬 기린 가부시키가이샤 | 항 ｃｄ27 항체 |
| PL2581113T3 (pl) | 2010-06-11 | 2018-11-30 | Kyowa Hakko Kirin Co., Ltd. | Przeciwciało anty-tim-3 |
| AU2011332043C1 (en) | 2010-11-23 | 2016-11-10 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
| CA2824719C (en) | 2011-01-19 | 2020-06-02 | Cantargia Ab | Anti-il1rap antibodies and their use for treating solid tumours |
| ES2670874T3 (es) | 2011-03-16 | 2018-06-01 | Argenx Bvba | Anticuerpos contra CD70 |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| ES2806146T3 (es) | 2011-09-22 | 2021-02-16 | Amgen Inc | Proteínas de unión al antígeno CD27L |
| WO2013093508A2 (en) | 2011-12-22 | 2013-06-27 | Oslo University Hospital Hf | Wnt pathway inhibitors |
| SG10201710574UA (en) | 2012-03-15 | 2018-02-27 | Janssen Biotech Inc | Human anti-cd27 antibodies, methods and uses |
| AU2013237419B2 (en) | 2012-03-21 | 2016-04-28 | Erytech Pharma | Medicament for the treatment of acute myeloid leukemia (AML) |
| WO2013177420A2 (en) | 2012-05-23 | 2013-11-28 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of bcr-abl positive lymphoblastic leukemias |
| JP6081582B2 (ja) | 2012-06-15 | 2017-02-15 | キュアジェニックス インコーポレイテッド | Ｗｎｔシグナリング阻害剤、組成物およびその用途としての化合物 |
| WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
| US20150315279A1 (en) | 2012-12-21 | 2015-11-05 | Cellerant Therapeutics, Inc. | Antibodies that bind membrane-bound il1rap |
| PT2956173T (pt) | 2013-02-14 | 2017-06-26 | Bristol Myers Squibb Co | Compostos de tubulisina, métodos de produção e utilização |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| US10081680B2 (en) | 2014-03-11 | 2018-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies |
| US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| US20180244792A1 (en) | 2015-09-10 | 2018-08-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Anti-fibrotic effect of cd70 |
| BR112018008891A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
| EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| WO2017156398A1 (en) | 2016-03-10 | 2017-09-14 | Assia Chemical Industries Ltd. | Solid state forms of venetoclax and processes for preparation of venetoclax |
| EP3442584B1 (en) | 2016-03-15 | 2021-07-28 | Seagen Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| BR112018075176A2 (pt) | 2016-06-09 | 2019-06-04 | Dr Reddys Laboratories Ltd | formas sólidas de venetoclax e processos para a preparação de venetoclax |
| WO2018009444A1 (en) | 2016-07-06 | 2018-01-11 | Concert Pharmaceuticals, Inc. | Deuterated venetoclax |
| CN107648185A (zh) | 2016-07-25 | 2018-02-02 | 常州爱诺新睿医药技术有限公司 | 一种无定型Venetoclax与药用辅料的固体分散体及其制备方法 |
| WO2018029711A2 (en) | 2016-08-12 | 2018-02-15 | Mylan Laboratories Limited | Process for the preparation of venetoclax |
| WO2018069941A2 (en) | 2016-10-14 | 2018-04-19 | Mylan Laboratories Limited | Polymorphic forms of venetoclax |
| EP3333167A1 (en) | 2016-12-09 | 2018-06-13 | LEK Pharmaceuticals d.d. | Solid forms of venetoclax |
| CZ201769A3 (cs) | 2017-02-06 | 2018-08-15 | Zentiva, K.S. | Pevné formy venetoclaxu |
| WO2018157803A1 (zh) | 2017-02-28 | 2018-09-07 | 苏州科睿思制药有限公司 | 维奈妥拉的晶型及其制备方法 |
| WO2018167652A1 (en) | 2017-03-13 | 2018-09-20 | Laurus Labs Limited | Process for preparation of amorphous form of venetoclax |
| CN107089981A (zh) | 2017-04-24 | 2017-08-25 | 杭州科耀医药科技有限公司 | 一种BCL‑2抑制剂Venetoclax的合成方法 |
| GB2567613A (en) | 2017-06-16 | 2019-04-24 | Argenx Bvba | Treatment for acute myeloid leukaemia |
| GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| TW202038958A (zh) | 2018-12-18 | 2020-11-01 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
-
2019
- 2019-12-16 TW TW108146057A patent/TW202038958A/zh unknown
- 2019-12-17 UY UY0001038511A patent/UY38511A/es unknown
- 2019-12-18 LT LTEPPCT/EP2019/085982T patent/LT3890740T/lt unknown
- 2019-12-18 EP EP23151526.3A patent/EP4218761A1/en active Pending
- 2019-12-18 ES ES19831677T patent/ES2941638T3/es active Active
- 2019-12-18 FI FIEP19831677.0T patent/FI3890740T3/fi active
- 2019-12-18 DK DK19831677.0T patent/DK3890740T3/da active
- 2019-12-18 US US16/719,220 patent/US11712468B2/en active Active
- 2019-12-18 CN CN201980082377.7A patent/CN113226317B/zh active Active
- 2019-12-18 CA CA3117282A patent/CA3117282A1/en active Pending
- 2019-12-18 KR KR1020217017438A patent/KR20210106428A/ko unknown
- 2019-12-18 PT PT198316770T patent/PT3890740T/pt unknown
- 2019-12-18 PL PL19831677.0T patent/PL3890740T3/pl unknown
- 2019-12-18 BR BR112021011684A patent/BR112021011684A2/pt unknown
- 2019-12-18 WO PCT/EP2019/085982 patent/WO2020127503A1/en unknown
- 2019-12-18 MX MX2021007350A patent/MX2021007350A/es unknown
- 2019-12-18 CN CN202211004780.8A patent/CN115920034A/zh active Pending
- 2019-12-18 AU AU2019409936A patent/AU2019409936A1/en active Pending
- 2019-12-18 HU HUE19831677A patent/HUE061710T2/hu unknown
- 2019-12-18 JP JP2021534948A patent/JP2022515077A/ja active Pending
- 2019-12-18 EP EP19831677.0A patent/EP3890740B1/en active Active
- 2019-12-18 SG SG11202105197UA patent/SG11202105197UA/en unknown
-
2021
- 2021-06-15 IL IL284015A patent/IL284015A/en unknown
-
2023
- 2023-06-14 US US18/334,582 patent/US20240033353A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2739612T3 (es) | Composición farmacéutica para el tratamiento de cáncer | |
| KR101980554B1 (ko) | 암의 치료 및/또는 예방용 의약 조성물 | |
| RU2639522C2 (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| FI3890740T3 (fi) | CD70 ja venetoklaksi, BCL-2-estäjä, yhdistelmähoito akuutin myelooisen leukemian hoitoon | |
| KR101968498B1 (ko) | 암의 치료 및/또는 예방용 의약 조성물 | |
| KR101980557B1 (ko) | 암의 치료 및/또는 예방용 의약 조성물 | |
| CN101282745B (zh) | 用cd37-特异性和cd20-特异性结合分子减少b-细胞 | |
| JP2018534933A5 (da) | ||
| JP2018516969A5 (da) | ||
| CN111936164A (zh) | 癌的治疗和/或预防用药物组合物 | |
| JP2019503361A (ja) | がんを治療するための抗ｐｄ−１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ | |
| CN109963592B (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2020515577A5 (da) | ||
| JP2011507932A5 (da) | ||
| WO2013018883A1 (ja) | 癌の治療及び／又は予防用医薬組成物 | |
| JP2020023499A (ja) | 抗ｃｘｃｒ４抗体によるｃ１０１３ｇ／ｃｘｃｒ４関連ワルデンシュトレームマクログロブリン血症の治療 | |
| JP2020527332A5 (da) | ||
| KR20200024823A (ko) | 급성 골수성 백혈병(acute myeloid leukaemia) 치료를 위한 항 cd70-항체 argx-110의 용도 | |
| CN110582303A (zh) | 使用抗cd25抗体-药物缀合物的组合疗法 | |
| JPWO2019246514A5 (da) | ||
| JPWO2020127503A5 (da) | ||
| JP2020522281A5 (da) | ||
| EP3452092B1 (en) | Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml) | |
| CN112367999A (zh) | 组合疗法 | |
| JPWO2019141732A5 (da) |